Tom is the founding CEO of Meitheal since its inception in 2017. In addition, Tom is also the founding President of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was established in April 2020. Prior to joining Meitheal and Xentria, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global partnerships, supply chain and product development. Before his work at Sagent, Tom held various roles at APP, now Fresenius Kabi North America, in Commercial Operations and Business Development, focusing on Portfolio Management and National Accounts.
Tom started his pharmaceutical career as a Sales Rep at Fougera, now Sandoz. During his tenure at Fougera, he held positions of increasing responsibilities eventually attaining the position of National Sales Manager. Tom earned an M.B.A. from Notre Dame University and a B.A. in Philosophy from Marquette University.
Victoria is Meitheal’s General Counsel & Corporate Secretary since its inception in 2017. In addition, Victoria is the General Counsel & Corporate Secretary of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was established in April 2020. Victoria came to Meitheal from Sagent Pharmaceuticals where she most recently served as Associate General Counsel and Assistant Secretary.
Prior to joining Sagent, Victoria was in private law practice in Chicago, Illinois. She has experience in acquisitions and dispositions, corporate and security transactions and intellectual property matters, including both domestic and international business transactions, litigation management and regulatory and quality assurance compliance.
Victoria earned her J.D. and LL.M in Intellectual Property from the John Marshall Law School and her B.S. in Operations Management & Information Systems from Northern Illinois University.
Jennifer serves as our Executive Vice President of Operations, she has been with Meitheal since it’s inception and has been a key part of the leadership team spearheading all operations including generics and biopharma project management, API sourcing, production and supply chain functions. Previously, she was Sr. Director of Project Management for Sagent Pharmaceuticals, and responsible for product development and drug development partnerships. Prior to her Sr. Director role, she held various positions at Sagent in global alliance management (focusing on commercial supply management), new product launches, and project management.
Jennifer started her pharmaceutical career at Hospira, (now Pfizer) as a program manager responsible for international alliances. Before entering the pharmaceutical industry, she was the Chemical Technology Division Manager at Alion Science and Technology, a Department of Defense contractor. She earned her Ph.D. in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Benedictine University.
Gail serves as our Vice President of Quality. Before joining our team, she was the Senior Director of Quality Assurance at
Sagent Pharmaceuticals. During her time at Sagent, she was responsible for the quality oversight of contract manufacturers,
quality systems, product launches, product release and the change control process.
Preceding her tenure at Sagent, Gail worked at Catalent Pharma Solutions as a Business Unit Director, overseeing multiple
manufacturing and packaging lines. This included directing the site audit program to support FDA, customer, and internal
audits as a Quality Manager. Her career began at Abbott Laboratories (now Pfizer), where she held various roles supporting
quality control, with an emphasis on microbiological testing and sterility assurance. Gail received her B.S. degree from
Loyola University Chicago.
Jay serves as our Vice President of Regulatory Affairs. He started his tenure with Meitheal as Director of Regulatory Affairs where he built the Regulatory department from the ground up. He continues to lead the department through numerous successful product approvals and launches. Previously, he was Senior Manager of Regulatory Affairs at Sagent Pharmaceuticals, and responsible for regulatory strategy in the areas of product development and post approval lifecycle management. Earlier in his career, he worked at APP Pharmaceuticals (now Fresenius Kabi North America) in Regulatory Affairs, specializing in product site transfers.
Jay started his pharmaceutical career in the laboratory, focusing on Quality Control and Quality Assurance. He earned a B.S. degree in Chemistry from the University of Illinois at Urbana-Champaign.
John serves as our Vice President of Corporate Strategy. Previously he held the position of Senior Director of Sales
where he developed and then implemented the strategy for Meitheal’s focus on contracting the portfolio of products
into the top 100 health systems in the United States. Before joining our team, he was Vice President of
Business Development at Simple Science, responsible for driving awareness with key life sciences clients to
their end customers through focused “in person” and virtual brand engagement.
Prior to Simple Science, John was Director of Marketing, Customer Relationship Management at Pfizer (formerly Hospira, Inc.)
developing the roadmap and executing strategies on how to best engage with the customer providing a best-in-class experience.
John has over 32 years of experience at both medical device (United States Surgical Corporation and Datex-Ohmeda) and pharmaceutical
(Abbott Laboratories, Hospira, Pfizer) organizations providing a unique understanding of
partnership engagements across the life sciences industry and the end customer.
Before transitioning to the healthcare industry, John started his professional career at General Electric, first completing
their sales training curriculum and then managing sales territories throughout the mid-west. He has a B.S. in Marketing from
Indiana University School of Business, Bloomington Indiana.
Jason serves as our Vice President of Sales and National Accounts. He started his career at Meitheal as a Director of National Accounts where he served as the primary contact with our GPO’s, IDN’s, wholesalers, and distributors before being promoted to Sr. Director where he was responsible for developing the strategic vision and business strategy that positions Meitheal to achieve market share, revenue and profit goals.
Before joining our team, Jason served as a Senior Manager of National Accounts at Fresenius Kabi where he was responsible for growing sales and profit with GPOs, IDNs, Oncology Distributors and 503B Compounding Organizations. During his tenure with Fresenius, he also served in various roles including Major Account Executive (Sales), Marketing and Field Sales.
Prior to his tenure at Fresenius, Jason worked at Cardinal Health as a Senior Sales Consultant, specializing in pharmacy distribution services and integrated corporate solutions. He started his career as a Contracts Manager for Bindley Western, a division of Cardinal Health, where he led the team responsible for managing pricing and membership eligibility of GPO contracts, individual manufacturer agreements, and generic sourcing programs. He earned a B.S. degree in Business from Indiana University – Indianapolis.
Ben serves as our Vice President of Commercial Operations, leading the product management, market intelligence, pricing, contracting and strategic portfolio areas for Meitheal. Before joining our team, Ben served as a Sr. Director of Marketing at Xellia Pharmaceuticals where he was responsible for downstream product launch process, developing downstream marketing plans, product development opportunities and various strategic initiatives.
Prior to his tenure at Xellia, Ben worked at Diplomat Pharmacy, Cardinal Health and Fresenius Kabi North America where he held various roles in marketing, portfolio management, product pricing and business strategy.
Before transitioning to the healthcare industry, Ben started his professional career at General Motors, holding various corporate finance roles in the Detroit and New York City areas. He earned his M.B.A. and B.B.A. in Finance from the University of Cincinnati.
Jay serves as our Vice President of Commercial Operations Specialty Pharma, leading Meitheal’s strategic expansion from its original focus as a generic injectable manufacturer, to include the development and commercialization of specialty branded biopharmaceuticals.
Prior to joining Meitheal, Jay held senior roles encompassing sales and marketing management, distribution and market access, and commercial/business development for organizations such as HRA Pharma Rare Diseases, Recordati Rare Diseases, Horizon Therapeutics and Lundbeck (formerly Ovation Pharma). He began his career at Forest Laboratories (now Abbvie).
Jay received a B.A. in Biology from William Jewell College and his M.B.A from the University of Chicago Booth School of Business.
